European randomized study of screening for prostate cancer - The Rotterdam pilot studies

International Journal of Cancer

Volumn 65, Issue 2, 1996, Pages 145-151

  Schröder, Fritz H ^a   Damhuis, Ronald A M ^c   Kirkels, Wim J ^a   De Koning, Harry J ^a   Kranse, Ries ^a   Nijs, Huub G T ^b   Bujenberg, Bert G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Public Health Service of the Rotterdam Region   (Netherlands)

^c Integraal Kankercentrum Rotterdam   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; PROSTATE CANCER;

AGE FACTORS; AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PILOT PROJECTS; PROSTATIC NEOPLASMS;

EID: 0030030272     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960117)65:2<145::AID-IJC4>3.0.CO;2-Z     Document Type: Article

References (25)

1. ADAMI, H.O., BARON, J.A. and ROTHMAN, K.J., Ethics of a prostate cancer screening trial. Lancet, 343, 958-960 (1994).
2. ADOLFSSON, J., STEINECK, G. and WHITMORE, W.F., JR., Recent results of management of palpable clinically localized prostatic cancer: a review and commentary. Cancer, 72, 310-322 (1993).
3. BANGMA, C.H., BLIJENBERG, B.G. and SCHRODER, F.H., Variabititeit van uitslagen van prostaatspecifiek antigen met 6 bepalingsmethoden. Ned. Tijdscnr. Geneeskd., 38, 813-817 (1994).
4. BENTVELSEN, F.M. and SCHRÖDER, F.H., Modalities available for screening for prostate cancer. Europ. J. Cancer, 29A, 804-811 (1993).
5. BOYLE, P. and ALEXANDER, F.E., Screening for prostate cancer: principles, design and evaluation. European Institute of Oncology Technical Report 94/005. European Institute of Oncology. Milan. Italy (1994).
6. BRAWER, M.K., BEATIE, J., WENER, M.H., VESSELLA, R.L., PRESTON, S.D. and LANGE, P.H., Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J. Urol., 150, 106-109 (1993).
7. CATALONA, W.J., RICHIE, J.P., AHMANN, F.R., HUDSON, M.A., SCARDINO, P.T., FLANIGAN, R.C., DE KERNION, J.B., RATLIFF, T.L., KAVOUSSI, L.R., DALKIN, B.L., WATERS, W.B., MACFARLANE, M. T. and SOUTHWICK, P.C., Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 151, 1283-1290 (1994)
8. CATALONA, W.J., SMITH, D.S., RATLIFF, T.L., DODDS, K.M., COPLEN, D.E., YUAN, J.J.J., PETROS, J.A. and ANDRIOLE, G.L., Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med., 324, 1156-1161 (1991).
9. CHADWICK, D.J., KEMPLE, T., ASTLEY, J.P., MACIVER, A.G., GILLATT, D.A., ABRAMS, P. and GINGELL, J.C., Pilot study of screening for prostate cancer in general practice. Lancet, 338, 613-615 (1991).
10. EPSTEIN, J.I., WALSH, P.C., CARMICHAEL, M. and BRENDLER, C.B., Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tlc) prostate cancer. J. Amer. Med Ass., 271, 368-374 (1994).
11. HAAS, G.P., MONTIE, J.E. and PONTES, J.E., The state of prostate cancer screening in the United States. Europ. Urol., 23, 337-347 (1993).
12. IRWN, M.B. and TRAPASSO, J.G., Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology, 44, 862-868 (1994).
13. JOHANSSOK, J.-E., ADAMI, H.-O., ANDERSSON, S.-O., BERGSTROM, R., HOLMBERG, L. and KRUSEMO, U.B., High 10-year survival rate in patients with early, untreated prostatic cancer. J. Amer. Med. Ass., 267, 2191-2196 (1992).
14. KRAMER, B.S., BROWN, M.L., PROROK, P.C., POTOSKY, A.L. and GOHAGAN, J.K., Prostate cancer screening: what we know and what we need to know. Ann. intern. Med., 119, 914-923 (1993).
15. LABRIE, F., DUPONT, A., SUBURU, R., CUSAN, L., TREMBLAY, M., GOMEZ, J.-L. and EMOND, J., Serum prostate specific antigen as pre-screening test for prostate cancer. J. Urol., 147, 846-852 (1992).
16. LU-YAO, G.L. and GREENBERG, E.R., Changes in prostate cancer incidence and treatment in USA. Lancet, 343, 251-254 (1994).
17. METTLIN, C., JONES, G., AVERETTE, H., GUSBERG, S.B. and MURPHY, G.P, Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA. 43, 42-46 (1993).
18. METTLIN, C., LEE, F., DRAGO, J., MURPHY, G.P. and INVESTIGATORS OF THE AMERICAN CANCER SOCIETY NATIONAL PROSTATE CANCER DETECTION PROJECT, The American Cancer Society National Prostate Cancer Detection Project. Cancer, 67, 2949-2958 (1991).
19. NIJS, H.G.T., CASPARIE, A.F., KIRKELS, W.J. and SCHRÖDER, F.H., Screening for prostate cancer: experiences and opinions in an urban community (Abstract). Int. Soc. Techn. Assessm. Health Care, 11th Ann. Meeting, Stockholm, Sweden (1995).
20. OHORI, M., WHEELER, T.M., DUNN, J.K., STAMEY, T.A. and SCARDINO, P.T., The pathological features and prognosis of prostate cancers detectable with current diagnostic tests. J. Urol., 152, 1714-1720 (1994).
21. RAVERY, V., BOCCON-GIBOD, L.A., DAUGE-GEFFROY, M.C., BILLEBAUD, T., DELMAS, V., MEULEMANS, A., TOUBLANC, M. and BOCCON-GIBOD, L., Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology, 44, 371-376 (1994).
22. SCHRÖDER, F.H., Prostate cancer: to screen or not to screen? Brit. Med. J, 306, 407-408 (1993).
23. SCHRÖDER, F.H. and BOYLE, P., Screening for prostate cancer-necessity or nonsense? Europ. J. Cancer, 29A, 656-661 (1993).
24. STORMONT, T.J., FARROW, G.M., MYERS, R.P., BLUTE, M.L., ZINCKE, H., WILSON, T.M. and OESTERLING, J.E., Clinical stage BO or Tlc prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology, 41, 3-8 (1993).
25. UICC TNM, Classification of malignant tumors, 4th ed. (2nd rev.), Springer-Verlag, Berlin (1992).